Drug Trial Radar · NCT05299658
An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS
Last checked: Nov 19, 2026Latest source record: Dec 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Nov 13, 2021
Primary completion
Jun 2026
Study completion Aug 2026
Sponsor
- Lead sponsor
- Clene NanomedicineIndustry
- Sponsor type
- Industry
- First posted
- Mar 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 30 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an optional open-label extension to participants that have completed the clinical trial CNMAu8.205.
Conditions
- Amyotrophic Lateral Sclerosis
Interventions
CNMAu8Drug
CNM-Au8 is an aqueous suspension of clean surfaced faceted nanocrystals consisting of gold atoms self-organized into crystals of various geometrical shapes (hexagonal bi-pyramid, pentagonal bi-pyramid, tetrahedron, decahedron, planar spheroids). Those choosing to participate in the OLE period will orally receive 30 mg of CNM-Au8, once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety measuresTime frame: Up to an estimated 96 weeks.
- Electromyography measuresTime frame: Up to an estimated 96 weeks.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Concord Hospital
Concord, New South Wales, Australia
Neuroscience Research Australia
Randwick, New South Wales, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.